News & Publications

Michael Kowarik, Head of Research will present at the 9th Annual National Carbohydrate Symposium at 9.05am MDT on May 09, 2013 at the Banff Park Lodge in Banff, Canada

Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Gréco steps down from the Chairmanship.

GlycoVaxyn AG, a leader in the development of innovative vaccines today announced that Janssen Pharmaceuticals, Inc. has signed an exclusive license agreement and enterd a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn's bio-conjugation technology.

GlycoVaxyn AG, a leader in the development of innovative vaccines today announced a collaboration with GlaxoSmithKline Biologicals (GSK) to develop new bacterial vaccines employing GlycoVaxyn's bio-conjugation technology.

Michael Kowarik, Head of Research, will present at the 5th Baltic Meeting on Microbial and Carbohydrates at 6.05 p.m. MSK, on September 03 at the Pushkarskaya Sloboda Hotel in Suzdal

Paula Carranza, MS Expert, will present at the 7th Annual Post-Translational Modification Congress at 5 p.m. CET, on September 27 at the Maritim Hotel in Berlin

Michael Stucky, Co-founder and CFO, will present at the 2012 BIO International Convention at 10:30 a.m. EDT, on June 20 at the Convention & Exhibition Center in Boston

Michael Kowarik, Head of Research, will present at the 2nd Annual Vaccine Congress London 2012 at 11:20 a.m. GMT, on April 02 at the Radisson Blu Portman Hotel in London

Michael Wacker, chief scientific officer, will present at the World Congress of Vaccine 2012 at 8:30 a.m. CST, on March 28 at the Beijing Continental Grand Hotel in Beijing

Philippe Dro, chief executive officer, will present at the Biotech Showcase 2012 at 10:30 a.m. PST, on January 9 at the Park 55 Wyndham in San Francisco

Philippe Dro, chief executive officer, will present at the Sofinnova Japan Biopharma Partnering Conference at 12:10 p.m. JST, October 4 at the Conrad Hotel in Tokyo

Presentation at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

First Annual Biotech in Europe Investor Forum & UBS Global Life Sciences Conference

Discuss Challenges and Opportunities in Vaccine Development

First important step towards the development of a mulitvalent Shigella vaccine against severe diarrheal disease

Program to leverage GlycoVaxyn Proprietary in vivo conjugation technology

GlycoVaxyn has commenced a Phase I clinical study with its vaccine candidate GVXN SD133 against Shigella dysenteriae.

GlycoVaxyn announced today that the world renowned vaccinologist Dr. Stanley A. Plotkin has been elected to its Supervisory Board.

GlycoVaxyn AG raises CHF 25 million in Financing led by Edmond de Rothschild Investment Partners.

GlycoVaxyn AG announces the appointment of Dr. Philippe Dro as Chief Executive Officer and member of the Supervisory Board. Dr. Dro brings to GlycoVaxyn nearly 20 years entrepreneurial experience in the life science industry.

GlycoVaxyn AG completes CHF 11.5 million Series A Financing. Former Aventis Pasteur President Michel Gréco appointed as chairman.

We are very pleased to announce that GlycoVaxyn has moved to larger facilities within the biotech cluster in Zurich-Schlieren.

GlycoVaxyn was awarded the Life Sciences Prize 2006, which is under the patronage of the Swiss Biotech Association and the BioValley Basel Association, on October 18th, 2006. The prize recognizes the scientific basis and the significant potential of for economic success of young Swiss startup companies.

GlycoVaxyn announces that it has completed its first institutional financing round in early July 2006, co-led by Index Ventures (www.indexventures.com) and Sofinnova Partners (www.sofinnova.fr). The proceeds from this financing will be used for the validation of GlycoVaxyn’s proprietary bacterial glycosylation technology. The funds are dedicated to advance GlycoVaxyn’ conjugated vaccine development programs against several bacterial pathogens of clinical significance. Furthermore, experimental work will address the widening of the scope of the technology, particularly by including different established carrier proteins as acceptors for bacterial sugar antigens.